Medpace (NASDAQ:MEDP) Receives Hold Rating from Jefferies Financial Group

Medpace (NASDAQ:MEDP)‘s stock had its “hold” rating reissued by Jefferies Financial Group in a report issued on Tuesday,Benzinga reports. They presently have a $515.00 price target on the stock, up from their previous price target of $490.00. Jefferies Financial Group’s target price would suggest a potential downside of 8.86% from the company’s current price.

A number of other analysts also recently weighed in on MEDP. Royal Bank Of Canada reduced their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Robert W. Baird dropped their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. BMO Capital Markets dropped their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Barclays decreased their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Three investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus price target of $463.33.

Medpace Stock Performance

Shares of MEDP opened at $565.09 on Tuesday. The company’s fifty day moving average is $457.31 and its 200 day moving average is $496.24. Medpace has a fifty-two week low of $306.70 and a fifty-two week high of $628.92. The stock has a market capitalization of $16.14 billion, a PE ratio of 35.52, a P/E/G ratio of 2.83 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same quarter in the prior year, the firm earned $3.67 earnings per share. Medpace’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts forecast that Medpace will post 17.04 earnings per share for the current year.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Medpace

Several institutional investors have recently added to or reduced their stakes in the company. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace during the fourth quarter valued at approximately $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the fourth quarter worth approximately $30,000. Basecamp Wealth Advisors LLC lifted its stake in shares of Medpace by 187.5% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after acquiring an additional 45 shares during the last quarter. Quarry LP bought a new stake in shares of Medpace during the 3rd quarter worth approximately $35,000. Finally, Bayban purchased a new position in Medpace during the 4th quarter valued at $44,000. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.